TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
01/01/2026 11:35 AM • The Schall Law Firm is seeking investors for a class action lawsuit against Telix Pharmaceuticals Limited (NASDAQ: TLX) for securities fraud. The company allegedly made false and misleading statements regarding its prostate cancer therapeutic candidates and overstated its supply chain quality during the period of February 21, 2025 to August 28, 2025. Investors who suffered losses are encouraged to contact the firm before January 9, 2026.
TLX - The company is accused of making false and misleading statements about its therapeutic candidates and supply chain quality, resulting in artificially inflated stock value and investor losses. These allegations of securities fraud and material misrepresentation are serious violations that negatively impact investor confidence and shareholder value.
Investing.com • Leo Miller